由于上述预期减值亏损的影响，叠加本集团医药分部因市场竞争加剧导致收入及毛利下降，预期本集团 于本期间将取得综合亏损净额约2.83亿港元至3.46亿港元，而本集团于截至2024年6月30日止6个月则取 得综合亏损净额约450万港元。 智通财经APP讯，华控康泰(01312)发布公告，预期本集团截至2025年6月30日止6个月将取得预期信贷亏 损模式下金融资产减值亏损约1.54亿港元至1.85亿港元;无形资产的减值亏损约1.13亿港元至1.24亿港元; 及健身业务分部商誉减值亏损约8040万港元至8880万港元。 ...

– 1 – 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 盈利警告 減值虧損 本公告乃由華控康泰集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據 香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及香港法例第571章 證券及期貨條例第XIVA部項下之內幕消息條文（定義見上市規則）而作出。 本公司董事會（「董事會」）謹此通知本公司股東（「股東」）及潛在投資者，基於本集團 截至二零二五年六月三十日止六個月（「本期間」）之最近期未經審核綜合管理賬目的 初步評估，預期本集團將錄得(i)預期信貸虧損模式下金融資產減值虧損介乎約 154.2百萬港元至185.3百萬港元；(ii)無形資產之減值虧損介乎約112.6百萬港元至 123.9百萬港元；及(iii)健身業務分部商譽減值虧損介乎約80.4百萬港元至88.8百萬 港元。 由於上述預期減值虧損之影響，疊加本集團醫藥分部因市場競爭加劇導致收入及毛 利下降，預期本集團於本期間將錄得綜合虧損 ...

格隆汇8月15日丨华控康泰(01312.HK)公布，公司将于2025年8月28日召开董事会会议，以（其中包括） 审议及通过集团截至2025年6月30日止六个月的中期业绩及其发布，以及审议派发中期股息的建议（如 有）。 ...

代表 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因依賴該等內容而引致之任何損失承擔任何責任。 董事會會議召開日期 華控康泰集團有限公司（「本公司」）宣佈，本公司謹訂於二零二五年八月二十八日 （星期四）舉行董事會（「董事會」）會議，藉以（其中包括）考慮及批准本公司及其附屬 公司截至二零二五年六月三十日止六個月之中期業績及其發佈，以及考慮派發中期 股息（如有）。 王飛飛 香港，二零二五年八月十五日 於本公告日期，董事會由四名執行董事王飛飛先生（主席兼總裁）、喬琳娜女士、郭 姿秀女士（財務總監）及劉劍焜先生；一名非執行董事黃俞先生；以及三名獨立非執 行董事鄧麗華博士、何昊洺博士及姚小民先生組成。 華控康泰集團有限公司 主席 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 FF301 致：香港交易及結算所有限公司 公司名稱: 華控康泰集團有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01312 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | 100,000,000,000 | HKD | | 0.002 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | | | 本月底結存 | | 100,000,000,000 | HKD | | 0.002 | HKD | | 200,000,000 | 本月底法定/註冊股本總額 ...

Financial Performance - The Group's revenue for the year ended December 31, 2024, was approximately HK$897.5 million, representing an increase of approximately 10.9% compared to HK$809.1 million in 2023[21]. - The Group reported a loss of approximately HK$99.0 million for the year, compared to a loss of approximately HK$61.1 million in 2023[21]. - The basic loss per share amounted to approximately HK$1.35 cents, an increase from approximately HK$0.52 cents in 2023[21]. - For the year ended 31 December 2024, the Group's revenue and gross profit amounted to approximately HK$897.5 million and HK$516.2 million, representing an increase of approximately 10.9% and 9.5% compared to the previous year[44]. - The Group's net loss for the year ended 31 December 2024 was approximately HK$99.0 million, an increase from a net loss of approximately HK$61.1 million in 2023, with basic loss per share at approximately HK$1.35 cents[44]. Dividend Policy - The Board has decided not to recommend any final dividend for the year ended December 31, 2024, consistent with the previous year[18]. - The Company aims to provide stable and sustainable returns to shareholders through its dividend policy, which was adopted in December 2018[19]. - The Company will consider various factors, including operational performance and future prospects, when proposing dividends[19]. - The Group's dividend policy aims for stable and sustainable returns to shareholders, but no final dividend was recommended for the year ended 31 December 2024[22][24]. Business Segments - The pharmaceutical business remains a key pillar for the Group, with plans for sales expansion and enhancement of core competitiveness through research and development[32]. - The fitness business in Singapore is set to introduce a new revenue line of Pilates Reformers in 2025, capitalizing on growing consumer interest[37]. - The Group's fitness business has recovered significantly from the impact of the COVID-19 pandemic, offsetting the adverse effects of decreased royalty fee income[45]. - For the year ended December 31, 2024, the revenue and gross profit of the Group's pharmaceutical business were approximately HK$682.1 million and HK$501.1 million, representing year-on-year increases of approximately 12.3% and 7.3% respectively[48]. - The profit from the pharmaceutical business segment decreased to approximately HK$7.0 million for the year ended December 31, 2024, down from approximately HK$69.6 million in 2023, primarily due to a one-off gain of approximately HK$110.5 million from the disposal of 66% equity interest in Shaanxi Life Care in 2023[49]. - The Group's fitness business revenue was approximately HK$215.4 million for the year ended December 31, 2024, an increase from approximately HK$202.0 million in 2023, with a loss of approximately HK$71.8 million, improved from a loss of approximately HK$81.5 million in 2023[68]. Operational Strategies - The Company is focused on enhancing its market position and exploring new opportunities for growth[17]. - The Group will continue to focus on cost control to mitigate the negative impacts on profitability from product price fluctuations[32]. - The introduction of effective marketing strategies has driven revenue and gross profit growth in the pharmaceutical business segment[45]. - The Group plans to explore new product launches and market entries in alignment with health consumption trends[31]. - The Group will opportunistically commence investment activities to identify a second growth curve[31]. Financial Health and Management - As of 31 December 2024, the Group maintained bank balances and cash reserves of approximately HK$80.6 million, an increase from HK$77.7 million as of 31 December 2023[72]. - The Group had outstanding borrowings repayable within one year of approximately HK$88.1 million, compared to HK$39.5 million in the previous year[73]. - The gearing ratio as of 31 December 2024 was 5.5%, up from 3.0% in 2023, indicating an increase in financial leverage[75]. - The Group's bank borrowings increased to approximately HK$85.5 million in 2024 from HK$28.8 million in 2023[80]. - The Group's staff costs were approximately HK$145.0 million as of 31 December 2024, down from HK$165.0 million in the previous year, reflecting a reduction in employee expenses[86]. Environmental, Social, and Governance (ESG) Initiatives - The report outlines the company's commitment to environmental, social, and governance (ESG) performance, focusing on sustainable operations and stakeholder interests[101]. - The governance structure includes a Board responsible for overseeing ESG policies and an Executive Committee for implementing related measures[109]. - The company has established a robust ESG management framework to ensure effective implementation of policies and risk management[110]. - The report adheres to four principles: materiality, quantitative, balance, and consistency, ensuring comprehensive and comparable ESG disclosures[102]. - The company emphasizes the importance of regular reviews and assessments of ESG performance and objectives by the management[116]. - The Group is developing and implementing an ESG management framework, including strategies and objectives, to enhance sustainable development[117]. - The Executive Committee is responsible for formulating policies and allocating budgets for ESG activities, aligning with the Group's overall business strategy[124]. - The Group has identified key stakeholders and established various communication channels to engage with them regarding ESG issues[128]. - A materiality assessment has been conducted to identify and prioritize key ESG issues relevant to the Pharmaceutical and Fitness businesses[138]. - The Group aims to comply with all applicable environmental requirements and continuously improve its environmental management practices[124]. Waste Management and Emissions - The company has implemented a solar energy generation project in its Beijing plant, covering over 30,000 square feet, fulfilling daily energy consumption needs and selling surplus energy to nearby plants[155]. - The company has replaced gas-fired boilers with electric steam generators to reduce exhaust gas emissions[160]. - The company has installed electrostatic fume purifiers and low-nitrogen burners to monitor and reduce exhaust gas emissions[156]. - The company conducts regular monitoring of exhaust gas emissions to ensure compliance with government regulations and standards[153]. - The company has engaged a qualified inspection company for self-monitoring of pollutant emissions to maintain stable emission levels[160]. - The company is committed to reducing greenhouse gas emissions and has initiated various energy-saving actions[156]. - The company has upgraded its wastewater treatment system to a three-tier deep treatment device to further reduce emissions of harmful gases[159]. - The company emphasizes diversity and inclusion, respecting the labor rights and human rights of all employees[151]. - The company has centralized the handling of hazardous wastes in accordance with relevant laws and regulations, ensuring detoxification treatments by qualified vendors before disposal[166]. - The Group aims to reduce the generation of hazardous and non-hazardous waste and has established waste reduction targets[192]. Resource Optimization - The Group aims to optimize resource usage by implementing the 3R Principle (Reduce, Reuse, Recycle) and improving water recycling utilization rates[199]. - The Group has focused on reducing water consumption in production and enhancing the maintenance and recharge of water sources[200]. - The Group has strengthened the management of raw materials to minimize pollutant generation and sought alternatives for difficult-to-process materials[200]. - The Group has improved operational management for wastewater treatment, significantly reducing technical difficulties and pollution[200]. - The Group's initiatives in resource optimization include energy conservation and water conservation across all business operations[199].

Financial Performance - The company's revenue for the year ended December 31, 2024, was HKD 897,521,000, representing a 10.9% increase from HKD 809,107,000 in 2023[3] - Gross profit for the same period was HKD 516,157,000, up 9.5% from HKD 471,292,000 in the previous year[3] - The company reported a loss before tax of HKD 97,979,000, compared to a loss of HKD 43,919,000 in 2023, indicating a significant increase in losses[3] - The total comprehensive loss for the year was HKD 100,501,000, compared to HKD 77,636,000 in 2023, reflecting a worsening financial position[4] - Basic loss per share increased to HKD 1.35 from HKD 0.52 in the previous year, indicating a decline in shareholder value[4] - The net loss for the fiscal year was approximately HKD 99.0 million, compared to a net loss of HKD 61.1 million in the previous year, with basic loss per share at HKD 1.35, up from HKD 0.52[30][31] Assets and Liabilities - Non-current assets decreased to HKD 1,030,423,000 from HKD 1,139,578,000, showing a reduction in the company's asset base[5] - Current liabilities increased to HKD 442,312,000 from HKD 383,600,000, indicating a rise in short-term financial obligations[6] - The equity attributable to shareholders decreased to HKD 978,701,000 from HKD 1,057,289,000, reflecting a decline in net worth[6] - Trade receivables at the end of the reporting period totaled HKD 108.7 million, slightly up from HKD 106.5 million in the previous year[27] - The company’s trade payables at the end of the reporting period were HKD 6.7 million, slightly down from HKD 6.7 million in the previous year, indicating stable payment practices[28] - The group's total borrowings increased to approximately HKD 88.1 million, with a debt-to-asset ratio of 5.5% compared to 3.0% the previous year[37] Revenue Breakdown - Pharmaceutical business revenue was HKD 682,086,000, up 12.3% from HKD 607,131,000 in the previous year[13] - Fitness business revenue increased to HKD 215,435,000, a rise of 6.7% from HKD 201,976,000 in 2023[13] - The pharmaceutical segment reported revenue and gross profit of approximately HKD 682.1 million and HKD 501.1 million, reflecting year-on-year increases of about 12.3% and 7.3%[32] - The fitness business generated revenue of approximately HKD 215.4 million, an increase from HKD 202.0 million in the previous year, despite a loss of approximately HKD 71.8 million[35] Expenses and Cost Management - The company incurred research and development expenses of HKD 34.6 million, up from HKD 20.8 million in the previous year, indicating a focus on innovation[23] - The total employee costs for the year were HKD 157.5 million, down from HKD 178.3 million, showing effective cost control measures[30] - The company reported a significant increase in promotional expenses, totaling HKD 427.6 million, compared to HKD 419.1 million in the previous year, reflecting increased marketing efforts[23] - The company recognized an impairment loss of HKD 18.8 million related to intangible assets in the fitness business, impacting overall profitability[30] Future Outlook and Strategy - The company plans to explore new product launches and market expansions while maintaining a focus on existing business growth[43] - The pharmaceutical business is expected to remain a key growth driver, with plans to enhance sales layout and core competitiveness through R&D[44] - The fitness business is set to launch a new revenue product line, Pilates Reformers, by 2025 to capitalize on the growing interest among Singapore consumers[45] - The company will continue to monitor its franchise operations in Taiwan to support business recovery in that region[45] Dividends and Reporting - The company did not declare any dividends for the fiscal year ending December 31, 2024, consistent with the previous year[26] - The board has decided not to recommend any final dividend for the year ending December 31, 2024[46] - The annual report for the year ending December 31, 2024, will be published on the Hong Kong Stock Exchange and the company's website[53] Regulatory and Compliance - The company has implemented revised Hong Kong Financial Reporting Standards, which may impact future financial reporting and classifications[8] - The company’s total liabilities classification was not significantly impacted by the new accounting policies applied this year[12] - The company has restructured its internal reporting framework, leading to changes in reportable segments[14] Subsidiary Performance - Tongfang Pharmaceutical recorded revenue and gross profit of approximately RMB 543.3 million and RMB 461.0 million for the year ending December 31, 2024, representing a year-on-year increase of approximately 17.4% and 11.4% respectively[33] - Chongqing Kangle's revenue increased by approximately 15.6% year-on-year to RMB 84.0 million, while gross profit decreased by approximately 4.9% to RMB 8.5 million due to market price fluctuations[34] Events After Reporting Period - There have been no significant events occurring after December 31, 2024, up to the date of this announcement[47] - The company has not purchased, sold, or redeemed any of its listed securities during the year ending December 31, 2024[52]

Financial Performance - The company reported a significant increase in revenue, achieving a total of $150 million for the first half of 2024, representing a 25% growth compared to the same period last year[29]. - The company reported a net income of $30 million, reflecting a 50% increase year-over-year[29]. - Revenue for the six months ended June 30, 2024, increased to HK$458,517,000, up 6.5% from HK$430,705,000 in the same period of 2023[33]. - Gross profit for the same period rose to HK$277,146,000, representing a 12.0% increase compared to HK$247,278,000 in 2023[33]. - The Group reported total revenue for the six months ended June 30, 2024, of HK$380,685,000, compared to HK$365,721,000 for the same period in 2023, reflecting an overall increase of approximately 4.4%[43]. - The Group's net loss for the six months ended 30 June 2024 was approximately HK$4.5 million, a turnaround from a net profit of approximately HK$21.4 million in 2023[116]. - Revenue and gross profit for the pharmaceutical business were approximately HK$345.4 million and HK$264.4 million, representing increases of approximately 3.8% and 6.8% compared to the same period in 2023[116]. User Engagement and Market Expansion - User data showed a 30% increase in active users, reaching 1.2 million by the end of June 2024[29]. - The company is planning to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[29]. - The fitness business generated revenue of HK$35,295,000 from personal training classes and HK$59,715,000 from membership packages, totaling HK$95,010,000 in fitness-related income for the period[43]. - The fitness business in Singapore is expected to maintain a promising outlook in the second half of 2024, with ongoing strategic initiatives aimed at solidifying business positioning[135]. Investment and Development - Investment in new product development increased by 15%, with a focus on innovative healthcare solutions[29]. - The company emphasized its commitment to sustainability, with plans to reduce carbon emissions by 25% by 2026[29]. - The company has made investments in intangible assets amounting to HK$1,925 during the first half of 2024, reflecting ongoing investment in growth[38]. - The Group aims to strengthen internal management and promote new product development while exploring emerging markets[120]. Financial Position and Cash Flow - Cash flow from operations was strong, totaling $20 million, which supports ongoing investments and operational stability[29]. - The company reported a net current assets position of HK$190,224,000, compared to HK$204,157,000 previously[36]. - The total comprehensive income for the period ended June 30, 2024, was HK$6,753, compared to a loss of HK$1,215 in the same period of 2023, reflecting a positive turnaround[39]. - Cash and cash equivalents at the end of the period were HK$68,663, down from HK$150,606 at the end of June 2023, indicating a decrease in liquidity[39]. - The Group's outstanding borrowings repayable within one year amounted to approximately HK$43.3 million, up from HK$39.5 million as of December 31, 2023[124]. Impairment and Losses - Loss for the period attributable to owners of the company was HK$4,532,000, a significant decline from a profit of HK$21,378,000 in the previous year[34]. - The total impairment losses recognized under the expected credit loss model for the six months ended June 30, 2024, amounted to HK$25,466,000, compared to HK$36,599,000 in the same period of 2023[57]. - An impairment loss on intangible assets related to the franchise agreement in Taiwan was recognized at approximately HK$13,559,000, with no impairment loss reported in the same period of 2023[54][56]. Corporate Governance and Management Changes - The company has maintained compliance with the Corporate Governance Code throughout the period, with a noted deviation regarding the roles of Chairman and CEO[146]. - The company is focusing on enhancing its corporate governance through new appointments in key positions[149]. - The changes in directors are aimed at strengthening the management team and improving operational efficiency[149]. - The Board of Directors has decided not to declare an interim dividend for the six months ended June 30, 2024, to retain funds for future business opportunities[136]. Legal Proceedings and Contingent Liabilities - The Group has contingent liabilities related to legal proceedings from 2019 and 2021, with no material progress made in either case[98]. - The 2019 Legal Proceedings involve claims against the Group regarding a profit guarantee shortfall for the financial years 2017 and 2018, with no trial date set as of the report date[99]. - The management believes the possibility of significant economic outflow related to both legal proceedings is remote[102]. Shareholder Information - China Health Management Investment Limited holds 3,172,778,000 shares, representing 56.77% of the total shareholding[140]. - The total number of shares held by substantial shareholders indicates a strong control over the company[140]. - The maximum number of shares that can be awarded under the Share Award Scheme is capped at 495,000,000 shares, with a limit of 49,500,000 shares for any selected employee[136].

Financial Performance - Revenue for the six months ended June 30, 2024, was HKD 458,517,000, an increase of 6.3% compared to HKD 430,705,000 for the same period in 2023[1] - Gross profit for the same period was HKD 277,146,000, with a gross margin of approximately 60.5%[1] - The net loss for the period was HKD 4,532,000, a significant decrease from a profit of HKD 21,378,000 in the prior year[1] - Other comprehensive income for the period was HKD 3,317,000, compared to a loss of HKD 20,419,000 in the previous year[2] - Basic earnings per share for the period was HKD 0.09, down from HKD 0.70 in the same period last year[2] - The company reported a net loss of HKD 3,672,000 for the six months ended June 30, 2024, compared to a profit of HKD 42,123,000 in the same period last year[16] - The net loss for the group was approximately HKD 4.5 million for the six months ended June 30, 2024, compared to a net profit of approximately HKD 21.4 million in the same period of 2023[26] Assets and Liabilities - Non-current assets totaled HKD 1,097,020,000 as of June 30, 2024, a decrease from HKD 1,139,578,000 at the end of 2023[3] - Current assets amounted to HKD 594,867,000, showing a slight increase from HKD 587,757,000 at the end of 2023[4] - Total liabilities decreased to HKD 226,513,000 from HKD 281,789,000 in the previous period[5] - The company reported a net asset value of HKD 1,060,731,000 as of June 30, 2024, compared to HKD 1,061,946,000 at the end of 2023[5] - The company’s cash and cash equivalents were HKD 68,663,000, down from HKD 77,659,000 at the end of 2023[4] - The total borrowings as of June 30, 2024, were approximately HKD 43.3 million, compared to HKD 39.5 million due within one year at the end of 2023[32] - The asset-liability ratio improved to 2.6% as of June 30, 2024, from 3.0% at the end of 2023[33] Revenue Breakdown - The pharmaceutical business generated revenue of HKD 345,390,000, up from HKD 332,721,000 in the previous year, indicating a growth of about 3.0%[13] - The fitness business reported revenue of HKD 113,127,000, compared to HKD 97,984,000 in the prior year, marking an increase of approximately 15.5%[13] - The pharmaceutical segment's revenue and gross profit were approximately HKD 345.4 million and HKD 264.4 million, reflecting increases of about 3.8% and 6.8% year-on-year[27] - The fitness segment's revenue increased to approximately HKD 113.1 million from HKD 98.0 million in the previous year, while the segment recorded a loss of approximately HKD 38.5 million, an improvement from a loss of HKD 52.1 million in 2023[31] Expenses and Costs - Research and development expenses totaled HKD 4,079,000, significantly reduced from HKD 13,638,000 in the previous year, a decrease of approximately 70.0%[16] - The total depreciation and amortization expenses amounted to HKD 49,685,000, down from HKD 57,780,000 in the previous year, a reduction of about 14.3%[16] - The total tax expense for the six months ended June 30, 2024, was HKD 12,921,000, compared to HKD 27,756,000 in the previous year, indicating a decrease of approximately 53.4%[15] - The group’s employee costs were approximately HKD 75,099,000, down from HKD 81,232,000 for the same period last year[37] Dividends and Shareholder Returns - No interim dividend was recommended for the six months ended June 30, 2024, consistent with the previous year[19] - Basic earnings per share for the six months ended June 30, 2024, were HKD 4,745, compared to HKD 39,138 for the same period in 2023, representing a significant decline[17] - The weighted average number of ordinary shares used for calculating basic earnings per share remained constant at 5,578,713,777 for both periods[17] Legal and Contingent Liabilities - The company is actively defending against legal claims related to a profit guarantee arrangement from a previous acquisition, with low likelihood of significant economic outflow[22][24] - The group has not reported any significant contingent liabilities as of June 30, 2024[24] Operational Insights - The group’s business primarily includes the manufacturing and sale of prescription drugs in China and operating fitness centers, along with franchise operations for royalty income[25] - The group anticipates a bright outlook for its fitness business in Singapore for the second half of 2024, despite rapid changes in the industry[39] - The group is focusing on enhancing product competitiveness through differentiated strategies and exploring new business models to adapt to market changes[38] - The group emphasizes a proactive approach to maintain its competitive edge in the fitness industry and plans to introduce new services and membership plans[39] Workforce and Employment - The group maintained a workforce of 717 employees as of June 30, 2024, slightly down from 720 employees as of December 31, 2023[37] Audit and Compliance - The audit committee reviewed the group's accounting principles and internal controls for the six months ending June 30, 2024[43] - No significant post-reporting date events have occurred since June 30, 2024[44]

Financial Performance - The Group's revenue for the year ended December 31, 2023, was approximately HK$809.1 million, a decrease of approximately 9.5% compared to HK$894.1 million in 2022[13]. - The Group reported a loss of approximately HK$61.1 million for the year, compared to a loss of approximately HK$52.8 million in 2022[13]. - Basic loss per share amounted to approximately HK$0.52 cent, an improvement from HK$0.74 cent in the previous year[17]. - The Board has resolved not to recommend any final dividend for the year ended December 31, 2023[18]. - For the year ended December 31, 2023, the Group's revenue and gross profit were approximately HK$809.1 million and HK$471.3 million, representing a decrease of approximately 9.5% and 6.9% compared to the previous year[39]. - The Group's net loss for the year was approximately HK$61.1 million, a decrease of approximately HK$48.6 million compared to a net loss of approximately HK$109.7 million in 2022[42]. Business Segments - The pharmaceutical business will face increased price competition due to changes in market demand and supply, but the Group aims for moderate growth through new product development and online marketing strategies in 2024[26][27]. - The Group plans to enhance its product mix and consolidate market share to create new earning growth opportunities in the pharmaceutical sector[26]. - The fitness business is expected to achieve sustainable year-on-year growth in new member sales and personal training revenue through innovative marketing strategies and personalized services[31][32]. - The Group's fitness business in Singapore has significantly improved as it recovers from the COVID-19 pandemic, partially offsetting the negative impacts from the pharmaceutical segment[44]. - The Group aims to enrich its product offerings and leverage emerging trends in the fitness industry to capitalize on growth opportunities in 2024[31]. - For the year ended December 31, 2023, the revenue and gross profit of the pharmaceutical business were approximately HK$607.1 million and HK$467.2 million, representing a year-on-year decrease of approximately 16.0% and 10.5% respectively[50]. One-time Gains and Losses - A one-time gain of approximately HK$110.5 million from the disposal of its entire equity interest in Shaanxi Life Care contributed to the improvement in the Group's performance despite unfavorable conditions[42]. - The significant increase in profit for the pharmaceutical business was mainly due to a one-off gain of approximately HK$110.5 million from the disposal of 66% equity interest in Shaanxi Life Care on May 9, 2023[52]. Challenges and Strategies - The decline in pharmaceutical revenue was attributed to adverse impacts from medical insurance policy adjustments and a weak macroeconomic environment affecting customer demand[51]. - The company is actively seeking new customers and orders in response to the challenges faced by Chongqing Kangle due to reduced export demand[60]. - Tongfang Pharmaceutical is facing pressures from new competitive products and is actively seeking countermeasures[58]. - The company’s fitness business was negatively impacted by increased salaries and commissions, reduced government subsidies related to COVID-19, and increased expected credit losses on receivables[63]. Cash Flow and Borrowings - As of 31 December 2023, the Group maintained bank balances and cash reserves of approximately HK$77.7 million, down from approximately HK$122.6 million in 2022[73]. - The Group's outstanding borrowings repayable within one year as of 31 December 2023 were approximately HK$39.5 million, significantly reduced from approximately HK$158.8 million in 2022[74]. - The gearing ratio (total borrowings over total assets) improved to 3.0% in 2023 from 12.4% in 2022[76]. - The Group's bank borrowings were approximately HK$28.824 million as of 31 December 2023, a decrease from approximately HK$206.555 million in 2022[82]. ESG and Corporate Governance - The Group has established a robust ESG governance structure consisting of three levels: the Board, the Executive Committee and management, and the working group and functional departments[108][109]. - The Board is responsible for overseeing the effective implementation of the Group's ESG policies and regularly reviewing the progress of relevant performance and objectives[115][116]. - The Executive Committee and management are tasked with developing and implementing relevant policies and measures in accordance with the ESG strategies set by the Board[116][119]. - The Group emphasizes the importance of stakeholder engagement, incorporating ESG elements into daily operations and assessing their long-term impact[125][126]. - The Group has appointed internal departments and external advisors to review operations and identify relevant ESG issues[126][127]. Environmental Management - The company is committed to operating sustainably while balancing stakeholder interests and positively impacting society[100]. - The Group aims to comply with all applicable environmental requirements and continuously improve its environmental management practices[119][122]. - The Group aims to reduce emissions, water consumption, and resource usage to minimize environmental impact[144]. - The establishment of an energy management system is expected to lower production costs and enhance economic efficiency[143]. - The Group emphasizes strict compliance with environmental protection laws and actively manages exhaust emissions, including formaldehyde and dust[143]. Waste Management - The company has centralized the handling of hazardous wastes and ensured detoxification treatments by qualified vendors before disposal[163]. - The company has implemented waste classification and signed agreements with local waste disposal companies to ensure proper handling of solid waste[162]. - The company aims to reduce hazardous and non-hazardous waste generation through material recovery and negotiation with suppliers[163]. - The Group has implemented waste sorting across all operations, enhancing hazardous waste management to reduce environmental risks[187]. Energy Consumption and Emissions - The company has implemented a Solar Energy Generation Project and various energy conservation measures to reduce emissions[184]. - The company has phased out high-pollution production lines and adopted natural gas as a fuel source to lower emissions[184]. - The clean energy generated from solar power as of 2023 was approximately 1,910,000 kWh, a decrease from approximately 2,490,000 kWh in 2022[194]. - The pharmaceutical business achieved energy savings of up to 40% through the implementation of frequency-controlled refrigeration units[195].